Additionally, while broad-spectrum antibiotics such as carbapenems and fluoroquinolones are typically the drug of choice to treat infections caused by extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae [6], carbapenem-resistant K. pneumoniae (CR-Kp) has been linked to resistance against these drugs, resulting in an escalated global risk of disease [7]. This evidence concerns the gene NPPA and infection.